

Edgar Filing: REPLIGEN CORP - Form 8-K

REPLIGEN CORP
Form 8-K
September 17, 2003

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) September 16, 2003

REPLIGEN CORPORATION

(Exact name of registration as specified in charter)

Delaware	0-14656	04-2729386
(State or other	(Commission	(IRS Employer
jurisdiction of	File Number)	Identification No.)
incorporation)		

41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA	02453
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code (781) 250-0111

(Former name or former address, if changed since last report.)

Item 5. Other Events and Required FD Disclosure.

Repligen Corporation (Nasdaq: RGEN) announced on September 16, 2003 that the United States District Court for the Eastern District of Michigan has issued a ruling in the lawsuit that Repligen and the University of Michigan are prosecuting against Bristol-Myers Squibb for correction of inventorship of certain CTLA4 patents issued to Bristol-Myers Squibb. A press release announcing the ruling is attached hereto as Exhibit 99.1.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits.

Exhibit No.	Exhibit
-----	-----
99.1	Press Release dated September 16, 2003.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the

Edgar Filing: REPLIGEN CORP - Form 8-K

registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Repligen Corporation

Dated: September 17, 2003

By: /s/ Walter C. Herlihy

Walter C. Herlihy
Chief Executive Officer and President

EXHIBIT INDEX

Exhibit No.

Exhibit

99.1

Press Release dated September 16, 2003.